Style | Citing Format |
---|---|
MLA | Shabani E, et al.. "Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma." Immunopathologia Persa, vol. 11, no. 2, 2025, pp. -. |
APA | Shabani E, Heidari SM, Roozitalab M, Zarei H, Mirshekari A, Ebrahimi S, Doshantapeh AG, Vatankhah SA, Dehghanighorbi M (2025). Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma. Immunopathologia Persa, 11(2), -. |
Chicago | Shabani E, Heidari SM, Roozitalab M, Zarei H, Mirshekari A, Ebrahimi S, Doshantapeh AG, Vatankhah SA, Dehghanighorbi M. "Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma." Immunopathologia Persa 11, no. 2 (2025): -. |
Harvard | Shabani E et al. (2025) 'Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma', Immunopathologia Persa, 11(2), pp. -. |
Vancouver | Shabani E, Heidari SM, Roozitalab M, Zarei H, Mirshekari A, Ebrahimi S, et al.. Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma. Immunopathologia Persa. 2025;11(2):-. |
BibTex | @article{ author = {Shabani E and Heidari SM and Roozitalab M and Zarei H and Mirshekari A and Ebrahimi S and Doshantapeh AG and Vatankhah SA and Dehghanighorbi M}, title = {Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma}, journal = {Immunopathologia Persa}, volume = {11}, number = {2}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Shabani E AU - Heidari SM AU - Roozitalab M AU - Zarei H AU - Mirshekari A AU - Ebrahimi S AU - Doshantapeh AG AU - Vatankhah SA AU - Dehghanighorbi M TI - Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma JO - Immunopathologia Persa VL - 11 IS - 2 SP - EP - PY - 2025 ER - |